



Information on AbbVie ABBV-8E12 Clinical Research Trial

Study Title: A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease

Study Investigators: Steven E. Arnold MD (Principal Investigator) and Aaron M. Koenig MD (Co-Investigator)

This flyer contains information about a research study being conducted by Drs. Arnold and Koenig at the MassGeneral Institute for Neurodegenerative Disease (MIND) at Massachusetts General Hospital. Participation in this study is completely voluntary, and whether or not you choose to participate will have no effect on the medical care you receive from anyone at Massachusetts General Hospital. Drs. Arnold and Koenig are looking for volunteers:

- between the ages of 55-85
- able to have an MRI scan
- a patient who has been diagnosed with Early Alzheimer's Disease?

The study is designed to examine the safety and efficacy of a drug that targets the protein tau in the brains of people with Alzheimer's disease. Research has shown that cognitive decline in patients with Alzheimer's disease may relate to levels of abnormal tau protein in the brain.

You may be eligible for this study if you have been diagnosed with Mild Cognitive Impairment (MCI) or Dementia due to Alzheimer's Disease.

Participation involves monthly visits to MGH facilities over approximately two years. There is no cost to you to participate in this study, and if you complete the study you will receive up to \$3500. The study will also pay for your parking and provide meal vouchers that can be redeemed in the MGH cafeteria.

You may not receive any direct health benefits as a result of participating in this research study. We hope that the findings from this study may help us find better ways to treat Alzheimer's Disease.

If you would like to learn more about the study, please contact the study coordinator, Parisa Oviedo, at (617) 643-2351 or poviedo@partners.org.